MTOR and breast cancer: Taken together, we detected mutations in multiple PI3K/AKT/mTOR signaling nodes that lead to increased pathway activation and have emerging clinical utility in luminal BC, e.g., through combination with EGFR inhibition as demonstrated in basal‐like BC (She et al, 2016).